Diagnosis of latent tuberculosis infection

Reichman and Hershfield's Tuberculosis: A Comprehensive, International Approach, Third Edition

Volumn , Issue , 2006, Pages 215-263

  Menzies, Dick ^a   Doherty, T Mark ^b  

^a MCGILL UNIVERSITY   (Canada)

^b STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 69249180339     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (254)

1. Koch R. An address on bacteriological research. Br Med J 1890; 2:380-383.
2. von Pirquet C. Frequency of tuberculosis in childhood. JAMA 1907; 52:675-678.
3. Mantoux MC. La voie intradermique en tuberculinotherapie. Presse Med 1912; 20:146-148.
4. Landi S, Held HR, Gupta KC. The multi-facets of tuberculin standardization. Dev Biol Stand 1975; 29:393-411.
5. Seibert FB, Glenn JT. Tuberculin purified protein derivative: preparation and analyses of a large quantity for standard. Am Rev Tuberc 1941; 44:9.
6. Landi S, Held HR, Tseng MC. Disparity of potency between stabilized and nonstabilized dilute tuberculin solutions. Am Rev Respir Dis 1971; 101:385-393.
7. Holden M, Dubin MR, Diamond PH. Frequency of negative intermediate-strength tuberculin sensitivity in patients with active tuberculosis. N Engl J Med 1971; 285(7):1506-1509.
8. Grzybowski S, Dorken E, Bates C. Disparities of tuberculins. Am Rev Resp Dis 1969; 100:86-87.
9. Guld J, Magnus K, Magnuson M. Instability of the potency of tuberculin dilutions. Am Rev Tuberc 1955; 72:126-128.
10. Swanson Beck J. Skin changes in the tuberculin test. Am Rev Respir Dis 1979; 120:59-65.
11. Hart P, Sutherland I, Thomas J. The immunity conferred by effective BCG and vole bacillus vaccines, in relation to individual variations induced tuberculin sensitivity and technical variations in the vaccines. Tubercle 1967; 48:201-210.
12. Youmans GP. Relation between delayed hypersensitivity and immunity in tuberculosis. Am Rev Respir Dis 1975; 111:109-118.
13. Rich AR. The Pathogenesis of Tuberculosis. Springfield, IL; Baltimore, MD: Charles C. Thomas, 1944.
14. Toews GB. Cell-mediated immunity. In: Pratter MR, Nelson S, eds. Cytokines and Pulmonary Infection. Part 1: Host-Pathogen Interactions in Pulmonary Infections. New York, New York: American Thoracic Society, 1997:39-50.
15. Rowe JF. A comparison between two commercial tuberculin products, Connaught and Parke Davis, Vancouver Island, 1972. Can J Public Health 1975; 66:241-246.
16. Lifson AR, Watters JK, Thompson S, Crane CM, Wise F. Discrepancies in tuberculin skin test results with two commercial products in a population of intravenous drug users. J Infect Dis 1993; 168:1048-1051.
17. Rupp ME, Schultz AW, Davis JC. Discordance between tuberculin skin test results with two commercial purified protein derivative preparations. J Infect Dis 1994; 169:1174-1175.
18. Lanphear BP, Linnemann CC, Cannon CG. A high false-positive rate of tuberculosis associated with Aplisol: an investigation among health care workers. J Infect Dis 1994; 169:703-704.
19. Muder RR, Brennen C, Yu KT. Choosing appropriate criteria for tuberculin positivity and conversion in a long-term care facility. Infect Contr Hosp Epidemiol 1993; 14(9):523-526.
20. Guld J, Bentzon MW, Bleiker MA, Griep WA, Magnuson M, Waaler H. Standardization of a new batch of purified tuberculin (PPD) intended for international use. Bull WHO 1958; 19:845-951.
21. World Health Organization. The WHO Standard Tuberculin Test. Geneva: World Health Organization, 1963.
22. Comstock GW, Edwards LB, Philip RN, Winn WA. A comparison in the United States of America of two tuberculins, PPD-S and PPD-RT 23. Bull WHO 1964; 31:161-170.
23. Murtagh K. Unreliability of the Mantoux test using 1 TU PPD in excluding childhood tuberculosis in Papua New Guinea. Arch Dis Child 1980; 55:795-799.
24. Duboczy BO, Brown BT. Multiple readings and determination of maximal intensity of tuberculin reaction. Am Rev Respir Dis 1960; 82:60-67.
25. Spiteri MA, Bowman A, Assefi AR, Clarke SW. Life threatening reaction to tuberculin testing. Br Med J 1986; 293:243-244.
26. Grzybowski S, Brown MT, Stothard D. Infections with atypical mycobacteria in British Columbia. Can Med Assoc J 1969; 100(19):896-900.
27. Dahlstrom AW. The instability of the tuberculin reaction. Observations on dispensary patients, with special reference to the existence of demonstrable tuberculous lesions and the degree of exposure to tubercle bacilli. Am Rev Tuberc 1940; 42:471-487.
28. Palmer CE. Tuberculin sensitivity and contact with tuberculosis. Am Rev Tuberc 1953; 68:678-694.
29. Guld J. Quantitative aspects of the intradermal tuberculin test in humans. Acta Tuberc Scand 1954; 30:26-36.
30. Long R. Canadian Tuberculosis Standards. 2000/2001 ed. Toronto: Canadian Lung Association, 2000.
31. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161:S221-S247.
32. Lalvani A, Nagvenkar P, Udwadia Z, et al. Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. J Infect Dis 2001; 183:469-477.
33. Lalvani A, Pathan AA, McShane H, et al. Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T-cells. Am J Respir Crit Care Med 2001; 163:824-828.
34. Mori T, Sakatani M, Yamagishi F, et al. Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med 2004; 170(1):59-64.
35. Pai M, Gokhale K, Joshi R, et al. Mycobacterium tuberculosis infection in health care workers in rural India: comparison of a whole-blood, interferon-y assay with tuberculin skin testing. JAMA 2005; 293(2746):2755.
36. Badger TL, Breitwieser ER, Muench H. Tuberculin Tine test: multiple-puncture intradermal technique compared with PPD-S, intermediate strength. Am Rev Respir Dis 1963; 87:338-351.
37. Furcolow ML, Watson KA, Charron T, Lowe J. A comparison of the Tine and Mono-vacc tests with the intradermal tuberculin test. Am Rev Respir Dis 1967; 96:1009-1027.
38. Fine MH, Furcolow ML, Chick EW, Bauman DS, Arik M. Tuberculin skin test reactions. Am Rev Respir Dis 1972; 106:752-758.
39. Donaldson JC, Elliot RC. A study of co-positivity of three multipuncture techniques with intradermal PPD Tuberculin. Am Rev Respir Dis 1978; 118:843-846.
40. Hansen JP, Falconer JA, Gallis HA, Hamilton JD. Inadequate sensitivity of tuberculin tine test for screening employee populations. J Occup Med 1982; 24(8):602-604.
41. Katz J, Krasnitz A, Kunofsky S. Comparative study of the Heaf and Mantoux tests. Am Rev Respir Dis 1967:1033-1038.
42. Carruthers KJM. Comparison of the Heaf (multiple puncture) and Mantoux tests using several tuberculins. Tubercle 1969; 50:22-41.
43. Chaparas SD. Multiple puncture tuberculin tests. Pediatr Infect Dis J 1987; 6(5): 496-497.
44. Research Committee of the British Thoracic Association. Reproducibility of the Tine tuberculin test. Br J Dis Chest 1982; 76:75-78.
45. Herzog C. Reason for variable response to tuberculin Tine test. Lancet 1981:417-418.
46. Wijsmuller G, Snider DEJ. Skin testing: a comparison of the jet injector with the Mantoux method. Am Rev Respir Dis 1975; 112:789-798.
47. Flynn P, Shenep J, Mao L, Crawford R, Williams B, Williams BG. Influence of needle gauge in Mantoux skin testing. Chest 1994; 106:1463-1465.
48. Comstock GW. False tuberculin test results. Chest 1975; 68(3):465-469.
49. Rhoades EV, Bryant RE. The influence of local factors on the reaction to tuberculin. 1. The effect of injection. Chest 1980; 77(2):190-193.
50. Duboczy BO. Repeated tuberculin tests at the same site in tuberculin-positive patients. Am Rev Respir Dis 1964; 90:77-86.
51. Glenchur H, Fossieck BE, Silverman M. An immediate skin test for the diagnosis of active pulmonary tuberculosis. Am Rev Respir Dis 1965; 92:741-748.
52. Kardjito T, Grange JM. A clinical evaluation of the diagnostic usefulness of an early dermal reaction to tuberculin: a failure to distinguish between tuberculosis and other respiratory disease. Tubercle 1985; 66:129-132.
53. Howard TP, Solomon DA. Reading the tuberculin skin test: who, when, and how? Arch Intern Med 1988; 148:2457-2459.
54. Slutkin G, Perez-Stable EJ, Hopewell PC. Time course and boosting of tuberculin reactions in nursing home residents. Am Rev Respir Dis 1986; 134:1048-1051.
55. Sokal JE. Measurement of delayed skin-test responses. N Engl J Med 1975; 293:501-502.
56. Bouros D, Zeros G, Panaretos C, Vassilatos C, Siafakas N. Palpation vs pen method for the measurement of skin tuberculin reaction (Mantoux test). Chest 1991; 99:416-419.
57. Bouros D, Maltezakis G, Tzanakis N, Tzortzaki E, Siafakas N. The role of inexperience in measuring tuberculin skin reaction (Mantoux test) by the pen or palpation technique. Respir Med 1992; 86:219-223.
58. Jordan TJ, Sunderam G, Thomas L, Reichman LB. Tuberculin reaction size measurement by the pen method compared to traditional palpation. Chest 1987; 92:234-236.
59. Longfield JN, Marsileth AM, Golden SM, Lazoritz S, Bohan S, Cruess DF. Interobserver and method variability in tuberculin skin testing. Pediatr Infect Dis 1984; 3:323-326.
60. Selby CD, Allen MB, Leitch AG. How well do the general public read Heaf skin tests? N Engl J Med 1975; 293:501-502.
61. Colp C, Goldfarb A, Wei I, Graney J. Patient’s self-interpretation of tuberculin skin tests. Chest 1996; 110(5):1275-1277.
62. Chaparas SD, Mac Vandiviere H, Melvin I, Koch G, Becker C. Tuberculin test: variability with the Mantoux procedure. Am Rev Respir Dis 1985; 132:175-177.
63. Bearman JE, Kleinman H, Glyer VV, LaCroix OM. A study of variability in tuberculin test reading. Am Rev Respir Dis 1964; 90:913-918.
64. Loudon RG, Lawson JR, Brown J. Variation in tuberculin test reading. Am Rev Respir Dis 1963; 87:852-861.
65. Erdtmann FJ, Dixon KE, Liewellyn CH. Skin testing for tuberculosis. Antigen and observer variability. JAMA 1974; 228(4):479-481.
66. Perez-Stable EJ, Slutkin G. A demonstration of lack of variability among six tuberculin skin test readers. Am J Public Health 1985; 75:1341-1343.
67. Carruthers KJM. Observer and experimental variation in tuberculin testing. Tubercle, Lond 1970; 51:48-67.
68. Pouchot J, Grasland A, Collet C, Coste J, Esdaile JM, Vinceneux P. Reliability of tuberculin skin test measurement. Ann Intern Med 1997; 126(3):210-214.
69. Griffith AH. Heaf test studies. Med Officer 1963; 110:161.
70. Tarlo SM, Day JH, Mann P, Day MP. Immediate hypersensitivity to tuberculin in-vivo and in-vitro studies. Chest 1977; 71(1):33-37.
71. Morrison JB. Lymphangitis after tuberculin tests. Br Med J 1984; 289:413.
72. Wright DN, Ledford DK, Lockey RF. Systemic and local allergic reactions to the tine test Purified Protein Derivative. JAMA 1989; 262(21):2999-3000.
73. DiMaio VJM, Froede CRC. Allergic reactions to the tine test. JAMA 1975; 233(7):769.
74. Hanson ML, Comstock GW. Efficacy of hydrocortisone ointment in the treatment of local reactions to tuberculin skin tests. Am Rev Respir Dis 1968; 97:472-473.
75. Reichman LB, O’Day R. The influence of a history of a previous test on the prevalence and size of reactions to tuberculin. Am Rev Respir Dis 1977; 115:737-741.
76. Snider DE. The tuberculin skin test. Am Rev Respir Dis 1982; 125:108-112.
77. Present PA, Comstock GW. Tuberculin sensitivity in pregnancy. Am Rev Respir Dis 1975; 112:413-416.
78. Snider DE, Farer LS. Package inserts for antituberculosis drugs and tuberculins. Am Rev Respir Dis 1985; 131:809-810.
79. World Health Organization. Further studies of geographic variation in naturally acquired tuberculin sensitivity. Bull WHO 1955; 12(1-2):63-83.
80. Stead WW, To T. The significance ofthe tuberculin skin test in elderly persons. Ann Intern Med 1987; 107:837-842.
81. Harrison BDW, Tugwell P, Fawcett IW. Tuberculin reaction in adult Nigerians with sputum-positive pulmonary tuberculosis. Lancet 1975:421-424.
82. Howard L, Klopfenstein MD, Steininger WJ, Woodruff CE. The loss of tuberculin sensitivity in certain patients with active pulmonary tuberculosis. Chest 1970; 57:530-534.
83. Kardjito T, Donosepoetro M. The Mantoux test in tuberculosis: correlations between the diameters of the dermal responses and the serum protein levels. Tubercle 1981; 62:31-35.
84. Selroos O, Pasternack A, Virolainen M. Skin test sensitivity and antigen induced lymphocyte transformation in Uraemia. Clin Exp Immunol 1973; 14:365-370.
85. Veen J. Aspects of Temporary Specific Anergy to Tuberculin in Vietnamese Refugees. Amsterdam: K.N.C.V., 1992:1-119.
86. Graham NMH, Nelson KE, Solomon L, et al. Prevalence of tuberculin positivity and skin test anergy in HIV-1-seropositive and -seronegative intravenous drug users. JAMA 1992; 267(3):369-373.
87. Huebner RE, Schein MF, Hall CA, Barnes SA. Delayed-type hypersensitivity anergy in human immunodeficiency virus-infected persons screened for infection with Mycobacterium tuberculosis. Clin Infect Dis 1994; 19:26-32.
88. Markowitz N, Hansen NI, Wilcosky TC, et al. Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons. Ann Intern Med 1993; 119:185-193.
89. Caiaffa WT, Graham NMH, Galai N, Rizzo RT, Nelson KE, Vlahov D. Instability of delayed-type hypersensitivity skin test anergy in human immunodeficiency virus infection. Arch Intern Med 1995; 155:2111-2117.
90. Gourevitch MN, Hartel D, Schoenbaum EE, Klein RS. Lack of association of induration size with HIV infection among drug users reacting to tuberculin. Am J Respir Crit Care Med 1996; 154:1029-1033.
91. Johnson MP, Coberly JS, Clermont HC, et al. Tuberculin skin test reactivity among adults infected with human immunodeficiency virus. J Infect Dis 1992; 166:194-198.
92. Okwera A, Eriki PP, Guay LL, Ball P, Daniel TM. Tuberculin reactions in apparently healthy HIV-seropositive and HIV-seronegative women—Uganda. Morb Mortal Wkly Rep 1990; 39:638-646.
93. Woodruff CE, Chapman TP. Tuberculin sensitivity in elderly patients. Am Rev Respir Dis 1971; 104:261-263.
94. Menzies D. Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med 1999; 159(1):15-21.
95. Battershill JH. Cutaneous testing in the elderly patient with tuberculosis. Chest 1980; 77(2):188-189.
96. Gordin FM, Perez-Stable EJ, Flaherty D, et al. Evaluation of a third sequential tuberculin skin test in a chronic care population. Am Rev Respir Dis 1988; 137:153-157.
97. Perez-Stable EJ, Flaherty D, Schecter G, Slutkin G, Hopewell PC. Conversion and reversion of tuberculin reactions in nursing home residents. Am Rev Respir Dis 1988; 137:801-804.
98. Pesanti EL. The negative tuberculin test. Tuberculin, HIV, and anergy panels. Am J Respir Crit Care Med 1994; 149:1699-1709.
99. Centers for Disease Control (CDC). Purified protein derivative (PPD)—tuberculin anergy and HIV infection: guidelines for anergy testing and management of anergic persons at high risk of tuberculosis. Morb Mort Wkly Rep 1991; 40(RR-5):27-33.
100. Kniker WT, Anderson CT, McBryde JL, Roumiantzeff M, Lesourd B. Multitest CMI for standardized measurement of delayed cutaneous hypersensitivity and cell-mediated immunity. Normal values and proposed scoring system for healthy adults in the U.S.A. Ann Allergy 1984; 52:75-82.
101. Guelar A, Gatell JM, Verdejo J, et al. A prospective study of the risk of tuberculosis among HIV-infected patients. AIDS 1993; 7:1345-1349.
102. Antonucci G, Girardi E, Raviglione MC, Ippolito G, for the GISTA. Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. JAMA 1995; 274(2):143-148.
103. Moreno S, Baraia-Etxaburu J, Bouza E, et al. Risk of developing tuberculosis among anergic patients infected with HIV. Ann Intern Med 1993; 119:194-198.
104. Yanai H, Uthaivoravit W, Mastro TD, et al. Utility of tuberculin and anergy skin testing in predicting tuberculosis infection in human immunodeficiency virus-infected persons in Thailand. Int J Tuberc Lung Dis 1997; 1(5):427-434.
105. Chin DP, Osmond D, Page-Shafer K, et al. Reliability of anergy skin testing in persons with HIV infection. Am J Respir Crit Care Med 1996; 153:1982-1984.
106. Center for Disease Control. Anergy skin testing and preventive therapy for HIV-infected persons. Morbid Mortal Weekly Rep 1997; 46(RR-15).
107. Villarino ME, Geiter LJ, Schulte JM, Castro KG. Purified protein derivative tuberculin and delayed-type hypersensitivity skin testing in migrant farm workers at risk for tuberculosis and HIV coinfection. AIDS 1994; 8:477-481.
108. Joncas JH, Robitaille R, Gauthier T. Interpretation of the PPD skin test in BCG-vaccinated children. Can Med Assoc J 1975; 113:127-128.
109. Horwitz O, Bunch-Christensen K. Correlation between tuberculin sensitivity after 2 months and 5 years among BCG vaccinated subjects. Bull WHO 1972; 47:49-58.
110. Ashley MJ, Siebenmann CO. Tuberculin skin sensitivity following BCG vaccination with vaccines of high and low viable counts. Can Med Assoc J 1967; 97:1335-1338.
111. Landi S, Ashley MJ, Grzybowski S. Tuberculin sensitivity following the intradermal and multiple puncture methods of BCG vaccination. Can Med Assoc J 1967; 97:222-225.
112. Badger TL, Ayvazian LF. Tuberculosis in nurses: clinical observations on its pathogenesis as seen in a fifteen year follow-up of 745 nurses. Am Rev Tuberc 1949; 60:305-331.
113. Heimbeck J. Incidence of tuberculosis in young adult women, with special reference to employment. Br J Tuberc 1938; 32:154-166.
114. Daniels M. Primary tuberculosis infection in nurses: manifestations and prognosis. Lancet 1944:165-170.
115. Stead WW. Management of health care workers after inadvertent exposure to tuberculosis: a guide for use of preventive therapy. Ann Intern Med 1995; 122:906-912.
116. Al-Kassimi FA, Al-Hajjaj MS, Al-Orainey IO, Bamgboye EA. Does the protective effect of neonatal BCG correlate with vaccine-induced tuberculin reaction? Am J Respir Crit Care Med 1995; 152:1575-1578.
117. Fine P, Sterne J, Ponnighaus J, Rees R. Delayed type hypersensitivity, mycobacterial vaccines and protective immunity. Lancet 1994; 344:1245-1249.
118. Comstock GW. Identification of an effective vaccine against tuberculosis. Am Rev Respir Dis 1988; 138:479-480.
119. Karalliede S, Katugha LP, Uragoda CG. The tuberculin response of Sri Lankan children after BCG vaccination at birth. Tubercle 1987; 68:33-38.
120. Menzies RI, Vissandjee B, Rocher I, St. Germain Y. The booster effect in two-step tuberculin testing among young adults in Montreal. Ann Intern Med 1994; 120: 190-198.
121. Menzies RI, Vissandjee B. Effect of Bacille Calmette-Guerin vaccination on tuberculin reactivity. Am Rev Respir Dis 1992; 145:621-625.
122. Hill PC, Brookes RH, Fox A, et al. Large-scale evaluation of enzyme-linked immu-nospot assay and skin test for diagnosis of Mycobacterium tuberculosis infection against a gradient of exposure in The Gambia. Clin Infect Dis 2004; 38(7): 966-973.
123. Schwartzman K, Loo V, Pasztor J, Menzies D. Tuberculosis infection among health care workers in Montreal. Am J Respir Crit Care Med 1996; 154:1006-1012.
124. Comstock GW, Edwards LB, Nabangwang H. Tuberculin sensitivity eight to fifteen years after BCG vaccination. Am Rev Respir Dis 1971; 103:572-575.
125. Jochem K, Tannenbaum TN, Menzies D. Prevalence of tuberculin skin test reactions among prison workers. Can J Public Health 1997; 88(3):202-206.
126. Menzies RI. The Determinants of the Prevalence of Tuberculous Infection among Montreal School children. Thesis for M.Sc. in Epidemiology and Biostatistics. Montreal: McGill University, 1989.
127. Brickman Helen F, Pierre BH. Prevalence of mycobacterial sensitivity in Montreal children. CMAJ 1974; 110:640-644.
128. Lind A, Larsson O, Bentzon MW, et al. Sensitivity to sensitins and tuberculin in Swedish children. Tubercle 1991; 72:29-36.
129. Bleiker MA. An investigation into specific and non-specific tuberculin sensitivity in schoolchildren in eighteen countries. Bull Int Union Tuberc 1968; 41:265-274.
130. Paul RC, Standord JL, Misljenovic O, Lefering J. Multiple skin testing of Kenyan schoolchildren with a series of new tuberculins. J Hyg Camb 1975; 75:303-313.
131. Lifschitz M. The value of tuberculin skin test as a screening test for tuberculosis among BCG-vaccinated children. Experience and reason—briefly recorded 1972:624-627.
132. Pabst HF, Kreth HW. Ontegeny of the immune response as a basis of childhood disease. J Pediatr 1980; 97(4):519-534.
133. Bahr GM, Chugh TD, Behbehani K, et al. Unexpected findings amongst the skin test responses to mycobacteria of BCG vaccinated Kuwaiti school children. Tubercle 1968; 68:105-112.
134. Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculosis meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 1993; 22:1154.
135. Schier DJ, Sternick JL, Allen EM, Moore VL. Genetic basis of BCG-induced suppression of delayed hypersensitivity. Nature 1981; 289:405-407.
136. Sepulveda RL, Heiba IM, King A, Gonzalez B, Elston RC, Sorensen RU. Evaluation of tuberculin reactivity in BCG-immunized siblings. Am J Respir Crit Care Med 1994; 149:620-624.
137. Menzies RI, Vissandjee B, Amyot D. Factors associated with tuberculin reactivity among the foreign-born in Montreal. Am Rev Respir Dis 1992; 146:752-756.
138. Kirschner RAJ, Parker BC, Falkinham JO III. Epidemiology of infection by nontuberculous mycobacteria. Am Rev Respir Dis 1992; 145:271-275.
139. George KL, Parker BC, Graft H, Falkinham JO. Epidemiology of infection by nontuberculous mycobacteria. II. Growth and survival in natural waters. Am Rev Respir Dis 1980; 122:89-94.
140. Parker BC, Ford MA, Gruft H, Falkinham JO. Epidemiology of infection by nontuberculous mycobacteria. IV. Preferential aerosolization of Mycobacterium intracellulare from natural waters. Am Rev Respir Dis 1983; 128:652-656.
141. Fry KL, Meissner PS, Falkinham JO. Epidemiology of infection by nontuberculous mycobacteria. VI. Identification and use of epidemiologic markers for studies of Mycobacterium avium, M. intracellulare, and M. scrofulaceum. Am Rev Respir Dis 1986; 134:39-43.
142. Jeanes CWL, Davies JW, McKinnon NE. Sensitivity to “Atypical” acid-fast mycobacteria in Canada. CMAJ 1969; 100:1-8.
143. Edwards LB, Acquiviva FA, Livesay VT, Palmer CE. An atlas of sensitivity to Tuberculin and PPD-B in the United States. Am Rev Respir Dis 1969; 99(suppl):1-132.
144. Bleiker MA, Misljenovic O, Styblo K. Study into the Risk of Tuberculous Infection in Schoolchildren in the City of Delft in the Period 1966-1985. In: Selected Papers. The Hague: Royal Netherlands Tuberculosis Association, 1997:19-24.
145. Ly HM, Trach DD, Long HT, et al. Skin test responsiveness to a series of new tuberculins of children living in three Vietnamese cities. Tubercle 1989; 70:27-36.
146. Corrah PT. Studies of Tuberculosis in the Gambia. In: Medical Research Council, Fajara, The Gambia. London: University College, 1994.
147. Robakiewicz M, Grzybowski S. Epidemiologic aspects of nontuberculous mycobacterial disease and of tuberculosis in British Columbia. Am Rev Respir Dis 1974; 109:613-620.
148. Margileth AM. Nontuberculous (atypical) mycobacterial disease. Semin Pediatr Infect Dis 1993; 4(4):307-315.
149. American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am Rev Respir Dis 1990; 142:940-953.
150. Huebner RE, Schein MF, Cauthen GM, Geiter LJ, O’Brien RJ. Usefulness of skin testing with mycobacterial antigens in children with cervical lymphadenopathy. Pediatr Infect Dis 1992; 11:450-456.
151. Huebner RE, Schein MF, Cauthen GM, et al. Evaluation of the clinical usefulness of mycobacterial skin test antigens in adults with pulmonary mycobacterioses. Am Rev Respir Dis 1992; 145:1160-1166.
152. von Reyn FC, Green PA, McCormick D, et al. Dual skin testing with Mycobacterium avium sensitin and purified protein derivative: an open study of patients with M. avium complex infection or tuberculosis. Clin Infect Dis 1994; 19:15-20.
153. Marks J, Palfreyman JM, Yates MD, Schaefer WB. A differential tuberculin test for mycobacterial infection in children. Tubercle 1977; 58:19-23.
154. Smith DT, Johnston WW. Single and multiple infections with typical and atypical mycobacteria. Am Rev Respir Dis 1964:899-912.
155. Palmer CE, Edwards LB, Hopwood L, Edwards PQ. Experimental and epidemiologic basis for the interpretation of tuberculin sensitivity. J Pediatr 1959; 55(4): 413-428.
156. American Thoracic Society. Diagnostic standards and classification oftuberculosis. Am Rev Respir Dis 1990; 142(3):725-735.
157. Magnusson M. Tuberculins, other mycobacterial sensitins and “new tuberculins”. Eur J Respir Dis 1986; 69:129-134.
158. Comstock GW, Edwards LB, Livesay VT. Tuberculosis morbidity in the US Navy: its distribution and decline. Am Rev Respir Dis 1974; 110:572-580.
159. Reichman LB, O’Day R. Tuberculous infection in a large urban population. Am Rev Respir Dis 1978; 117:705-712.
160. Cross ER, Hyams KC. Tuberculin skin testing in US Navy and Marine Corps personnel and recruits, 1980-1986. Am J Public Health 1990; 80:435-438.
161. Barry MA, Shirley L, Grady MT, et al. Tuberculosis infection in urban adolescents: results of a school-based testing program. Am J Public Health 1990; 80: 439-441.
162. Trump DH, Hyams KC, Cross ER, Struewing JP. Tuberculosis infection among young adults entering the US navy in 1990. Arch Intern Med 1993; 153:211-216.
163. Reichman LB, Felton CP, Edsall JR. Drug dependance, a possible new risk factor for tuberculosis disease. Arch Intern Med 1979; 139:337-339.
164. Van den Brande P, Demedts M. Four-stage tuberculin testing in elderly subjects induces age-dependent progressive boosting. Chest 1992; 101:447-450.
165. Dorken E, Grzybowski S, Allen EA. Significance of the tuberculin skin test in the elderly. Chest 1992; 2:237-240.
166. Friedman LN, Sullivan GM, Bevilaqua RP, Loscos R. Tuberculosis screening in alcoholics and drug addicts. Am Rev Respir Dis 1987; 136:1188-1192.
167. Grzybowski S, Allen EA, Black WA, et al. Inner-city survey for tuberculosis: evaluation of diagnostic methods. Am Rev Respir Dis 1987; 135(6):1311-1315.
168. Paul EA, Lebowitz SM, Moore RE, Hoven CW, Bennett BA, Chen A. Nemesis revisited: tuberculosis infection in a New York City men’s shelter. Am J Public Health 1993; 83(12):1743-1745.
169. Zolopa AR, Hahn JA, Gorter R, et al. HIV and tuberculosis infection in San Francisco’s homeless adults. JAMA 1994; 272(6):455-461.
170. Nolan CM, Elarth AM. Tuberculosis in a cohort of Southeast Asian refugees: a five-year surveillance study. Am Rev Respir Dis 1988; 137:805-809.
171. Morse DL, Hansen RE, Swalbach G, Redmond SR, Grabau JC. High rate of tuberculin conversion in Indochinese refugees. JAMA 1982; 248(22):2983-2986.
172. Fitzpatrick S, Johnson J, Shragg P, Felice ME. Health care needs of Indochinese refugee teenagers. Pediatrics 1987; 79(1):118-124.
173. Ormerod LP. Tuberculosis screening and prevention in new immigrants 1983-88. Respir Med 1990; 84:269-271.
174. Spinaci S, De Virgilio G, Bugiani M, Linari D, Bertolaso G. Tuberculin survey among Afghan refugee children. Tuberculosis control programme among Afghan refugees in North West frontier province (NWFP) Pakistan. Tubercle 1989; 70:83-92.
175. Godue CB, Goggin P, Gyorkos TW. L’allergie tuberculinique chez les revendi-cateurs du statut de refugie nouvellement arrives au Canada. CMAJ 1988; 139:41-44.
176. Blum RN, Polish LB, Tapy JM, Catlin BJ, Cohn DL. Results of screening for tuberculosis in foreign-born persons applying for adjustment of immigration status. Chest 1993; 103:1670-1674.
177. Hong Kong Chest Service/Tuberculosis Research Centre MBMRC. A controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Am Rev Respir Dis 1989; 139:871-876.
178. van Zwanenberg D. Tuberculous infection in the home. Tubercle 1955; 36: 238-244.
179. Zaki MH, Lyons HA, Robins AB, Brown EP. Tuberculin sensitivity. NY State J Med 1976; 76:2138-2143.
180. Grzybowski S, Barnett GD, Styblo K. Contacts of cases of active pulmonary tuberculosis. Bull IUAT 1975; 50:90-106.
181. Van Geuns HA, Meijer J, Styblo K. Results of contact examination in Rotterdam, 1967-1969. Bull Int Union Tuberc 1975; 50:107-121.
182. Karalus NC. Contact screening procedures for tuberculosis in Auckland. NZ Med J 1988; 101:45-49.
183. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320(9):545-550.
184. Hong Kong Chest Service/Tuberculosis Research Centre MBMRC. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992; 145:36-41.
185. Rolinck-Werninghaus C, Magdorf K, Stark K, et al. The potential of recombinant antigens ESAT-6, MPT63 and mig for specific discrimination of Mycobacterium tuberculosis and M. avium infection. Eur J Pediatr 2003; 162(7-8):534-536.
186. Horwitz O, Wilbek E, Erickson PA. Epidemiological basis of tuberculosis eradication. Longitudinal studies on the risk of tuberculosis in the general population of a low-prevalence area. Bull WHO 1969; 41:95-113.
187. Veening GJJ. Long term isoniazid prophylaxis. Controlled trial on INH prophylaxis after recent tuberculin conversion in young adults. Bull Int Union Tuberc 1968; 41:169-171.
188. Sutherland I. The evolution of clinical tuberculosis in adolescents. Tubercle 1966; 47:308.
189. Comstock GW, Ferebee SH, Hammes LM. A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis 1967; 95(6):935-943.
190. Edwards LB, Acquaviva FA, Livesay VT. Identification of tuberculous infected: dual tests and density of reaction. Am Rev Respir Dis 1973; 108:1334-1339.
191. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. Adv Tuberc Res 1969; 17:28-106.
192. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 1974; 99(2):131-137.
193. Groth-Peterson E, Knudsen J, Wilbeck E. Epidemiological basis of tuberculous eradication in Denmark. Bull WHO 1959; 21(1):5-49.
194. Dawson-Saunders B, Trapp RG. Basic and Clinical Biostatistics. Norwalk: Appleton & Lange, 1990.
195. Magnus K, Edwards LB. The effect of repeated tuberculin testing on postvaccination allergy. Lancet 1955; ii:643-644.
196. Narain RO. Interpretation of the repeat tuberculin test. Tubercle 1968; 49:92.
197. Cauthen GM, Snider DE, Onorato IM. Boosting of tuberculin sensitivity among Southeast Asian refugees. Am J Respir Crit Care Med 1994; 149:1597-1600.
198. Thompson NJ, Glassroth JL, Snider DE, Farer LS. The booster phenomenon in serial tuberculin testing. Am Rev Respir Dis 1979; 119:587-597.
199. Bass JB, Serio RA. The use of repeated skin tests to eliminate the booster phenomenon in serial tuberculin testing. Am Rev Respir Dis 1981; 123:394-396.
200. Valenti WM, Andrews BA, Presley BA, Reifler CB. Absence of the booster phenomenon in serial tuberculin skin testing. Am Rev Respir Dis 1982; 125:323-325.
201. Gross TP, Israel E, Powers P, Cauthen G, Rose J. Low prevalence of the booster phenomenon in nursing-home employees in Maryland. Maryland Med J1984; 35:107-109.
202. Richards NM, Nelson KE, Batt MD, Hackbarth D, Heidenreich JG. Tuberculin test conversion during repeated skin testing, associated with sensitivity to nontuberculous mycobacteria. Am Rev Respir Dis 1979; 120:59-65.
203. Alvarez S, Karprzyk DR, Freundl M. Two-stage skin testing for tuberculosis in a domiciliary population. Am Rev Respir Dis 1987; 136:1193-1196.
204. Barry MA, Regan AM, Kunches LM, et al. Two-stage tuberculin testing with control antigens in patients residing in two chronic disease hospitals. JAGS 1987; 35:147-153.
205. Burstin SJ, Muspratt JA, Rossing TH. The tuberculin test. Studies of the dynamics of reactivity to tuberculin and Candida antigen in institutionalized patients. Am Rev Respir Dis 1986; 134:1072-1074.
206. Webster CT, Gordin FM, Matts JP, et al. Two-stage tuberculin skin testing in individuals with human immunodeficiency virus infection. Am J Respir Crit Care Med 1995; 151:805-808.
207. Hecker MT, Johnson JL, Whalen CC, Nyole S, Mugerwa RD, Ellner JJ. Two-step tuberculin skin testing in HIV-infected persons in Uganda. Am J Respir Crit Care Med 1997; 155:81-86.
208. Lifson AR, Grant SM, Lorvick J, et al. Two-step tuberculin skin testing of injection drug users recruited from community-based settings. Int J Tuberc Lung Dis 1997; 1(2):128-134.
209. Morse DL, Hansen RE, Grabau JC, Cauthen G, Redmond SR, Hyde RW. Tuberculin conversions in Indochinese refugees. Am Rev Respir Dis 1985; 132:516-519.
210. Sepulveda RL, Burr C, Ferrer X, Sorensen RU. Booster effect of tuberculin testing in healthy 6-year-old school children vaccinated with Bacillus Calmette-Guerin at birth in Santiago, Chile. Pediatr Infect Dis J 1988; 7(578):581.
211. Friedland IR. The booster effect with repeat tuberculin testing in children and its relationship to BCG vaccination. S Afr Med J 1990; 77:387-389.
212. Sepulveda RL, Ferrer X, Latrach C, Sorensen RU. The influence of Calmette-Guerin Bacillus immunization on the booster effect of tuberculin testing in healthy young adults. Am Rev Respir Dis 1990; 142:24-28.
213. Stead WW, Lofgren JP, Warren E, Thomas C. Tuberculosis as an endemic and nosocomial infection among the elderly in nursing homes. N Engl J Med 1985; 23:1483-1487.
214. Canadian Thoracic Society. In: FitzGerald JM, ed. Canadian Tuberculosis Standards. Ottawa: Canadian Lung Association, 1996.
215. American Thoracic Society. The tuberculin skin test. Am Rev Respir Dis 1981; 124:356-363.
216. Stead WW, To T, Harrison RW, Abraham JH. Benefit-risk considerations in preventive treatment for tuberculosis in elderly persons. Ann Intern Med 1987; 107:843-845.
217. March-Ayuela Pd. Choosing an appropriate criterion for true or false conversion in serial tuberculin testing. Am Rev Respir Dis 1990; 141:815-820.
218. Bass JB, Sanders RV, Kirkpatrick MB. Choosing an appropriate cutting point for conversion in annual tuberculin skin testing. Am Rev Respir Dis 1985; 132: 379-381.
219. Guld J. Response to BCG vaccination. In: Palmer CE, Magnus K, Edwards LB, eds. Studies by the WHO Tuberculosis Research Office. Geneva: World Health Organization, 1953:51-56.
220. Youmans GP. Tuberculosis. Philadelphia: W.B. Saunders Company, 1979.
221. Triep WA. De tuberculinereactie (Dutch only). The Haag, Netherlands: Royal Netherlands Tuberculosis Association (KNCV), 1957.
222. Wasz-Hockert O. On the period of incubation in tuberculosis. Ann Med Fenn 1947; 96:764-772.
223. Wallgren A. The time-table of tuberculosis. Tubercle 1948; 29:245-251.
224. Poulsen A. Some clinical features of tuberculosis. I. Incubation period. Acta Tuberc Scand 1954; 24(16):311-346.
225. Greenaway C, Palayew M, Menzies D. Yield of casual contact investigation by the hour. Int J Tuberc Lung Dis 2003; 7(12):S479-S485.
226. Houk VN, Kent DC, Sorenson K, Baker JH. The eradication of tuberculosis infection by isoniazid chemoprophylaxis. Arch Environ Health 1968; 16:46-50.
227. Felten MK, Van Der Merwe CA. Random variation in tuberculin sensitivity in schoolchildren. Am Rev Respir Dis 1989; 140:1001-1006.
228. Hsu KHK. Tuberculin reaction in children treated with Isoniazid. Am J Dis Child 1983; 137:1090-1092.
229. Gordon FM, Perez-Stable EJ, Reid M, et al. Stability of positive tuberculin tests: Are boosted reactions valid? Am Rev Respir Dis 1991; 144:560-563.
230. Grzybowksi S, McKinnon NE, Tuters L, Pinkus G, Philipps R. Reactivations in inactive pulmonary tuberculosis. Am Rev Respir Dis 1966; 93:352-360.
231. Grzybowski S, Fishaut H, Rowe J, Brown A. Tuberculosis among patients with various radiologic abnormalities, followed by the chest clinic service. Am Rev Respir Dis 1971; 104:605-608.
232. Medlar EM. Apical scars: their etiological relationship to tuberculous infection. Am Rev Tuberc 1947; LV(6):511-516.
233. Anderson P, Munk ME, Pollock S, Doherty TM. Specific immune-based diagnosis of tuberculosis. Lancet 2000; 356:1099-1104.
234. Pai M, Riley LW, Colford JM Jr. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 2004; 4(12):761-776.
235. Streeton JA, Desem N, Jones SL. Sensitivity and specificity of a gamma interferon blood test for tuberculosis infection. Int J Tuberc Lung Dis 1998; 2(6):443-450.
236. Pottumarthy S, Morris AJ, Harrison AC, Wells VC. Evaluation of the tuberculin gamma interferon assay: potential to replace the Mantoux skin test. J Clin Microbiol 1999; 37(10):3229-3232.
237. Johnson PDR, Stuart RL, Grayson ML, et al. Tuberculin-purified protein derivative-, MPT-64-, and ESAT-6-stimulated gamma interferon responses in medical students before and after Mycobacterium bovis BCG vaccination and in patients with tuberculosis. Clin Diagn Lab Immunol 1999; 6(6):934-937.
238. Stuart RL, Olden D, Johnson PD, et al. Effect of anti-tuberculosis treatment on the tuberculin interferon-gamma response in tuberculin skin test (TST) positive health care workers and patients with tuberculosis. Int J Tuberc Lung Dis 2000; 4(6): 555-561.
239. Mazurek GH, LoBue PA, Daley CL, et al. Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA 2001; 286(14):1740-1747.
240. Brock I, Munk ME, Kok-Jensen A, Anderson P. Performance of whole blood IFN-y test for tuberculosis diagnosis based on PPD or the specific antigens ESAT-6 and CFP-10. Int J Tuberc Lung Dis 2001; 5(5):462-467.
241. Fietta A, Meloni F, Cascina A, et al. Comparison of a whole-blood interferon-gamma assay and tuberculin skin testing in patients with active tuberculosis and individuals at high or low risk of Mycobacterium tuberculosis infection. Am J Infect Control 2003; 31(6):347-353.
242. Vekemans J, Lienhardt C, Sillah JS, et al. Tuberculosis contacts but not patients have higher gamma interferon responses to ESAT-6 than do community controls in the Gambia. Infect Immun 2001; 69(10):6554-6557.
243. Ravn P, Munk ME, Andersen AB, et al. Reactivation of tuberculosis during immunosuppressive treatment in a patient with a positive QuantiFERON-RD1 test. Scand J Infect Dis 2004; 36(6-7):499-501.
244. Brock I, Weldingh K, Leyten EM, Arend SM, Ravn P, Andersen P. Specific T-cell epitopes for immunoassay-based diagnosis of Mycobacterium tuberculosis infection. J Clin Microbiol 2004; 42(6):2379-2387.
245. Pathan AA, Wilkinson KA, Klenerman P, et al. Direct ex vivo analysis of antigen-specific IFN-y-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J Immunol 2001; 167:5217-5225.
246. Chapman AL, Munkanta M, Wilkinson KA, et al. Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells. AIDS 2002; 16(17):2285-2293.
247. Scholvinck E, Wilkinson KA, Whelan AO, Martineau AR, Levin M, Wilkinson RJ. Gamma interferon-based immunodiagnosis of tuberculosis: comparison between whole-blood and enzyme-linked immunospot methods. J Clin Microbiol 2004; 42(2):829-831.
248. Bellete B, Coberly J, Barnes GL, et al. Evaluation of a whole-blood interferon-gamma release assay for the detection of Mycobacterium tuberculosis infection in 2 study populations. Clin Infect Dis 2002; 34(11):1449-1456.
249. US Food and Drug Administration. WRAIR study. A comparison of Quanti-FERON-TB interferon-gamma test with the TST for detection of M. tuberculosis infection in military recruits. Quanti FERONTB-P010033. Summary of safety and effectiveness, January 5, 2005. Found in FDA document on safety and effectiveness of QuantiFERON. http://www.fda.gov/cdrh/pdf/p010033b.doc.
250. Katial RK, Hershey J, Purohit-Seth T, et al. Cell-mediated immune response to tuberculosis antigens: comparison of skin testing and measurement of in vitro gamma interferon production in whole-blood culture. Clin Diagn Lab Immunol 2001; 8(2):339-345.
251. Piersimoni C, Callegaro A, Nista D, et al. Comparative evaluation of two commercial amplification assays for direct detection of Mycobacterium tuberculosis complex in respiratory specimens. J Clin Microbiol 1997; 35(1):193-196.
252. Brock I, Weldingh K, Lillebaek T, Follmann F, Andersen P. Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. Am J Respir Crit Care Med 2004; 170(1):65-69.
253. Ewer K, Deeks J, Alvarez L, et al. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 2003; 361(9364):1168-1173.
254. US Food and Drug Administration. QuantiFERONTB-P010033. Summary of safety and effectiveness, January 5, 2005. http://www.fda.gov/cdrh/pdf/p010033b.doc.